Positron Emission Tomography in Detecting Testicle Cancer

Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Jan 26, 2003

Keywords

ClinConnect Summary

OBJECTIVES:

* Assess the ability of fludeoxyglucose F 18 positron emission tomography to predict relapse requiring adjuvant chemotherapy in patients with high-risk stage I non-seminomatous or mixed seminoma/non-seminomatous germ cell tumor of the testis who are on current management protocols.

OUTLINE: This is a multicenter study.

Patients receive fludeoxyglucose F 18 (FDG) IV followed 1 hour later by positron emission tomography (PET) imaging. Patients with metastatic disease identified by FDG PET imaging may receive adjuvant chemotherapy according to the standard clinical practice at e...

Gender

MALE

Eligibility criteria

• DISEASE CHARACTERISTICS:
• • Histologically confirmed non-seminomatous or mixed seminoma/non-seminomatous germ cell tumor of the testis with evidence of vascular (lymphatic or venous) invasion in primary specimen
• • Clinical stage I on the basis of clinical examination, chest x-ray, and CT scan of the chest, abdomen, and pelvis
• • Negative post-orchidectomy tumor markers (alpha-fetoprotein and beta human chorionic gonadotropin)
• • High-risk disease
• PATIENT CHARACTERISTICS:
• • Age
• • Any age
• • Performance status
• • Not specified
• • Life expectancy
• • Not specified
• • Hematopoietic
• • Not specified
• • Hepatic
• • Not specified
• • Renal
• • Not specified
• • Other
• • No evidence of active inflammatory or infective diseases
• • No other disease or prior malignancy that would preclude study
• PRIOR CONCURRENT THERAPY:
• • Biologic therapy
• • Not specified
• • Chemotherapy
• • Not specified
• • Endocrine therapy
• • Not specified
• • Radiotherapy
• • Not specified
• • Surgery
• • See Disease Characteristics
• • No more than 8 weeks since prior orchidectomy
• • Other
• • No prior positron emission tomography scans